Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

CompletedOBSERVATIONAL
Enrollment

329

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

July 31, 2023

Conditions
Heart Failure
Interventions
DEVICE

Bodyport Cardiac Scale

The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.

Trial Locations (8)

19140

Temple University - Lewis Katz School of Medicine, Philadelphia

27710

Duke University Medical Center, Durham

29653

Self Regional Healthcare Research Center, Hodges

30501

The Heart Center of Northeast Georgia Medical Center, Gainesville

32405

Cardiovascular Institute of Northwest Florida, Panama City

33472

RecioMed Clinical Research Network, Inc., Boynton Beach

48201

Wayne State University, Detroit

66160

University of Kansas School of Medicine, Kansas City

Sponsors
All Listed Sponsors
collaborator

Duke Clinical Research Institute

OTHER

lead

Bodyport Inc.

INDUSTRY

NCT04882449 - Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events | Biotech Hunter | Biotech Hunter